All In Biotech

Drug Trial Radar · NCT05167760

Efficacy of Topical Apraclonidine for the Treatment of Ocular Synkinesis

Last checked: Nov 19, 2026Latest source record: Jul 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Dec 2025

Primary completion

Nov 2027

Study completion Nov 2028

Sponsor

Lead sponsor
University of Alabama at BirminghamAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 22, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine efficacy of apraclonidine for patients with ocular synkinesis, who are seen in the UAB Facial Nerve Clinic.

Conditions

  • Synkinesis
  • Facial Nerve Palsy

Interventions

  • ApraclonidineDrug

    1-2 drops per eye every 8 hours for 2 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Improvement in synkinesis symptomsTime frame: Baseline - 20 minutes after study drug administration

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.